MR DWI/FLAIR Measurement V1.0
Olea Medical • Radiology • 04/26/2023
Device Purpose
MR DWI/FLAIR Measurement V1.0 is an image processing software application that automates the analysis of MR DWI and FLAIR sequences, utilizing algorithms including a deep learning-based brain extraction tool to compute ADC maps and derive quantitative metrics like hypointense areas and contralateral FLAIR ratios. This system aims to assist clinicians by providing adjunctive, standardized measurements from MR neuroimaging studies for enhanced assessment, without altering original images or serving as a standalone diagnostic tool.
Summary
MR DWI/FLAIR Measurement V1.0 is an image processing software application designed for the analysis of MR Diffusion-Weighted Imaging (DWI) and MR FLAIR images. It assists trained medical professionals by computing an Apparent Diffusion Coefficient (ADC) map from DWI data and extracting key metrics, such as the hypointense area on the ADC map. Additionally, the software analyzes FLAIR series, including the calculation of ratios with contralateral information, and automatically generates relative and normalized FLAIR images. The system takes FLAIR and DWI sequences as input, processes them through an automated pipeline, and outputs results that can be integrated into existing imaging workflows and viewed on DICOM viewers, functioning as an adjunctive tool and not for standalone diagnosis. A key technological feature is the inclusion of a deep learning-based Diffusion Brain Extraction Tool (BET) to filter noise and exclude background pixels from raw DWI images prior to output computation; this algorithm was trained and validated on diverse datasets from multiple institutions and manufacturers (Siemens, GE, Philips, Canon). The software operates as a dockerized application, allowing flexible deployment on various technical platforms that support DICOM data handling. Performance testing, including a comparative clinical image study against its predicate device, demonstrated strong agreement. For relative FLAIR measurements, the average bias was 0.004 with 95% limits of agreement between -0.013 and +0.021. For normalized FLAIR, the average bias was 0.05 with 95% limits of agreement between -0.100 and +0.199. DICE similarity coefficients for ADC hypointense area segmentations on FLAIR images were excellent, ranging from 0.816 to 0.976 for both relative and normalized FLAIR analyses.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the performance of the deep learning-based Brain Extraction Tool (BET) compare to traditional (non-AI) brain extraction methods in terms of accuracy and processing time for DWI images?; What is the clinical significance or typical range for the "hypointense area on ADC" and "ratios with contralateral information on FLAIR images," and in what specific neurological conditions are these metrics most informative?; Can the MR DWI/FLAIR Measurement V1.0 software be customized or fine-tuned by users for specific scanner protocols or patient populations beyond the initial training data?; What are the computational requirements (e.g., GPU, RAM) for running the MR DWI/FLAIR Measurement V1.0 docker, particularly the deep learning BET component, and how does this impact integration into existing hospital IT infrastructures?; Given the software's reliance on DICOM metadata, how robust is it to variations or incompleteness in metadata from different MRI scanners and institutions, and what are the fallback mechanisms?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM, SaaSBOM, OBOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, HBOM, CBOM, VDR/VEX. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly